1. Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform.
- Author
-
Hu, Jing, Wu, Jiali, Jin, Qihuang, Zhang, Ling, Shen, Ning, Shu, Yiyang, Cheng, Lu, Zhang, Jian, Hu, Guangyi, Lv, Kangjia, Jian, Qizhi, Chen, Hui, Zhang, Fang, and Sun, Xiaodong
- Subjects
ADIPOGENESIS ,THYROID eye disease ,THERAPEUTICS ,VASCULAR endothelial growth factor receptors ,TREATMENT delay (Medicine) - Abstract
Our study developed an easy-to-use and reproducible platform with high-throughput drug screening, a 3D culture model and an in-vivo model for TED studies, which was based on a TED patient-derived OF-CL with proliferative and adipogenic properties and without severely perturbing genotype inheritance. Thyroid eye disease (TED), the most frequent orbital disease and the leading cause of proptosis in adults, is a debilitating, disfiguring, and even sight-threatening disease.[1] Drugs as alternative options are required for TED patients who need surgery to control orbital compression. Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient-derived preclinical platform The stromal vascular fraction (SVF) was isolated from the OAT of a 35-year-old female TED patient who underwent decompression surgery, and cultured in dishes for primary orbital fibroblasts (OFs). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF